Cara Therapeutics Inc has a consensus price target of $11.73, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Needham, and Needham on May 15, 2024, May 14, 2024, and April 10, 2024. With an average price target of $4.53 between HC Wainwright & Co., Needham, and Needham, there's an implied 488.74% upside for Cara Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/15/2024 | Buy Now | 367.53% | HC Wainwright & Co. | Oren Livnat | → $3.6 | Reiterates | Buy → Buy | Get Alert |
05/14/2024 | Buy Now | 549.35% | Needham | Joseph Stringer | → $5 | Reiterates | Buy → Buy | Get Alert |
04/10/2024 | Buy Now | 549.35% | Needham | Joseph Stringer | → $5 | Reiterates | Buy → Buy | Get Alert |
03/28/2024 | Buy Now | 549.35% | Needham | Joseph Stringer | → $5 | Reiterates | Buy → Buy | Get Alert |
03/06/2024 | Buy Now | 1198.7% | Canaccord Genuity | Sumant Kulkarni | $11 → $10 | Maintains | Buy | Get Alert |
03/05/2024 | Buy Now | 549.35% | Needham | Joseph Stringer | → $5 | Reiterates | Buy → Buy | Get Alert |
01/22/2024 | Buy Now | 549.35% | Needham | Joseph Stringer | $6 → $5 | Maintains | Buy | Get Alert |
12/19/2023 | Buy Now | 224.68% | HC Wainwright & Co. | Oren Livnat | $7 → $2.5 | Maintains | Buy | Get Alert |
12/18/2023 | Buy Now | 679.22% | Needham | Joseph Stringer | $22 → $6 | Maintains | Buy | Get Alert |
11/14/2023 | Buy Now | 29.87% | Piper Sandler | David Amsellem | $12 → $1 | Downgrade | Overweight → Neutral | Get Alert |
10/19/2023 | Buy Now | 809.09% | HC Wainwright & Co. | Oren Livnat | $15 → $7 | Maintains | Buy | Get Alert |
08/08/2023 | Buy Now | 1458.44% | Piper Sandler | David Amsellem | $13 → $12 | Maintains | Overweight | Get Alert |
08/08/2023 | Buy Now | 2757.14% | Needham | Joseph Stringer | → $22 | Reiterates | Buy → Buy | Get Alert |
06/27/2023 | Buy Now | 3536.36% | Stifel | Annabel Samimy | → $28 | Reiterates | Buy → Buy | Get Alert |
06/27/2023 | Buy Now | 2237.66% | Jefferies | Dennis Ding | → $18 | Reiterates | Buy → Buy | Get Alert |
05/16/2023 | Buy Now | 1848.05% | HC Wainwright & Co. | Oren Livnat | $20 → $15 | Maintains | Buy | Get Alert |
05/16/2023 | Buy Now | 419.48% | B of A Securities | Jason Gerberry | $6 → $4 | Maintains | Underperform | Get Alert |
05/16/2023 | Buy Now | 2757.14% | Needham | Joseph Stringer | → $22 | Reiterates | → Buy | Get Alert |
04/18/2023 | Buy Now | 2757.14% | Needham | Joseph Stringer | → $22 | Reiterates | → Action List Buy | Get Alert |
04/04/2023 | Buy Now | 2757.14% | Needham | Joseph Stringer | → $22 | Reiterates | → Buy | Get Alert |
03/08/2023 | Buy Now | 679.22% | B of A Securities | Jason Gerberry | $13 → $6 | Downgrade | Neutral → Underperform | Get Alert |
03/07/2023 | Buy Now | 1977.92% | JP Morgan | Daniel Wolle | $19 → $16 | Maintains | Overweight | Get Alert |
03/07/2023 | Buy Now | 3146.75% | Canaccord Genuity | Sumant Kulkarni | $29 → $25 | Maintains | Buy | Get Alert |
03/07/2023 | Buy Now | 2757.14% | Needham | Joseph Stringer | $26 → $22 | Maintains | Buy | Get Alert |
03/07/2023 | Buy Now | 1588.31% | Piper Sandler | David Amsellem | $25 → $13 | Maintains | Overweight | Get Alert |
03/07/2023 | Buy Now | 2497.4% | HC Wainwright & Co. | Oren Livnat | $25 → $20 | Maintains | Buy | Get Alert |
02/17/2023 | Buy Now | 3276.62% | Needham | Joseph Stringer | → $26 | Reiterates | → Buy | Get Alert |
02/14/2023 | Buy Now | 3146.75% | HC Wainwright & Co. | Oren Livnat | $30 → $25 | Maintains | Buy | Get Alert |
03/14/2022 | Buy Now | 3666.23% | Canaccord Genuity | Sumant Kulkarni | $33 → $29 | Maintains | Buy | Get Alert |
03/14/2022 | Buy Now | 3796.1% | HC Wainwright & Co. | Oren Livnat | $35 → $30 | Maintains | Buy | Get Alert |
The latest price target for Cara Therapeutics (NASDAQ: CARA) was reported by HC Wainwright & Co. on May 15, 2024. The analyst firm set a price target for $3.60 expecting CARA to rise to within 12 months (a possible 367.53% upside). 15 analyst firms have reported ratings in the last year.
The latest analyst rating for Cara Therapeutics (NASDAQ: CARA) was provided by HC Wainwright & Co., and Cara Therapeutics reiterated their buy rating.
The last upgrade for Cara Therapeutics Inc happened on March 8, 2022 when JP Morgan raised their price target to $20. JP Morgan previously had a neutral for Cara Therapeutics Inc.
The last downgrade for Cara Therapeutics Inc happened on November 14, 2023 when Piper Sandler changed their price target from $12 to $1 for Cara Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cara Therapeutics was filed on May 15, 2024 so you should expect the next rating to be made available sometime around May 15, 2025.
While ratings are subjective and will change, the latest Cara Therapeutics (CARA) rating was a reiterated with a price target of $0.00 to $3.60. The current price Cara Therapeutics (CARA) is trading at is $0.77, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.